Business Wire | Aug 3, 2020 07:30AM EDT

Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020

Aug. 03, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 03, 2020--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it will host a live conference call and webcast at 8:00am ET on Friday, August 7, 2020 to discuss second quarter 2020 financial results and business progress, as well as provide an introduction to the newest members of its management team. Participating on the call will be Tony Kingsley (President and CEO), Ted Myles (CFO and Head of Business Operations), and Yung Chyung (Chief Medical Officer).

Conference Call and WebcastTo access the live conference call, please dial 833-519-1308 (domestic) or 914-800-3874 (international), and refer to conference ID 5627485. A webcast of the call will also be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company's website for approximately 90 days following the presentation.

About Scholar RockScholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn ( https://www.linkedin.com/company/scholar-rock/).

Scholar Rock(r) is a registered trademark of Scholar Rock, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005120/en/

CONTACT: Scholar Rock Contact: Investors Catherine Hu chu@scholarrock.com 917-601-1649 Media Contact: The Yates Network Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412